Skip to main content

Market Overview

FDA Has Approved Egalet's ARYMO ER

Share:
FDA Has Approved Egalet's ARYMO ER

The U.S. Food and Drug Administration approved Egalet Corp (NASDAQ: EGLT)'s ARYMO ER on Monday to expand the industry for opioid-based pain-management treatments. The announcement bodes well for Egalet, the shares of which responded with a 17-percent jump.

Trading was halted at 12:24.33 p.m. pending news. At the time of the freeze, shares rested at $9.12 following a day-opening price of $7.97, up 15.44 percent.

Prior to Monday, about 61 percent of the company’s shares had been shorted — a condition that may induce a short squeeze when trading resumes.

This activity follows a tumultuous year for Egalet investors.

In October, shares dropped 5 percent after the FDA delayed ARYMO ER’s Prescription Drug User Fee Act date and shook investor confidence. However, delays are typical in FDA opioid proceedings, and Cantor Fitzgerald analysts reiterated a company Buy rating at the time.

Egalet plans to launch the drug in the first quarter of 2017.

 

Related Articles (EGLT)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas News Health Care Reiteration FDA Analyst Ratings Best of Benzinga

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com